Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001

You may also be interested in...



Novartis Consumer Health Reshuffled, Functional Foods On Sales Block

Novartis is reorganizing its consumer health division by grouping together three businesses - OTC drugs, infant and baby and medical nutrition - and operating animal health and Ciba Vision as separate units, the firm stated during a year-end analysts call Feb. 7

Novartis Consumer Health Reshuffled, Functional Foods On Sales Block

Novartis is reorganizing its consumer health division by grouping together three businesses - OTC drugs, infant and baby and medical nutrition - and operating animal health and Ciba Vision as separate units, the firm stated during a year-end analysts call Feb. 7

Novartis Consumer Health Reshuffled, Functional Foods On Sales Block

Novartis is reorganizing its consumer health division by grouping together three businesses - OTC drugs, infant and baby and medical nutrition - and operating animal health and Ciba Vision as separate units, the firm stated during a year-end analysts call Feb. 7

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel